The drug, made by Pfizer, has many positives: It had an 89% reduction in the potential risk of hospitalization and death in unvaccinated persons while in the clinical demo that supported the EUA, a range that was high ample to prompt the National Institutes of Health (NIH) to prioritize it more than other COVID-19 treatments. Nevertheless, which